Descartes-08 for Lupus

Overseen By Cartesian Clinical Trials

Age: Any Age

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Cartesian Therapeutics

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

50 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis

Are You a Good Fit for This Trial?

This trial is for children, adolescents, and young adults aged 12 or older with autoimmune disorders like lupus, juvenile myasthenia gravis, dermatomyositis, or vasculitis. They must have moderate disease symptoms and a history of systemic treatment. Consent from the patient or guardian is required.

Inclusion Criteria

I am 12 years old or older.

My symptoms are moderate, not mild or severe.

I have received systemic treatment before.

Exclusion Criteria

Hemoglobin < 8.0 g/dL

Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient

I do not have hepatitis C or, if I tested positive for it, my viral load is undetectable.

What Are the Treatments Tested in This Trial?

Interventions

• Descartes-08

Trial Overview

The trial tests Descartes-08's safety and effectiveness in managing autoimmune conditions in younger patients. It aims to see how well they tolerate the drug and if it improves their symptoms.

How Is the Trial Designed?

Group I: Part 2: Decartes-08 infusions once weekly for 6 weeks Experimental Treatment 1 Intervention

Descartes-08 infusions at the maximum tolerated dose level from Part 1.

Group II: Part 1: Decartes-08 to establish Maximum tolerated dose Experimental Treatment 1 Intervention

Intra-patient dose escalation arm with three dose levels over the course of six infusions of cell product.

Who Is Running the Clinical Trial?

Cartesian Therapeutics

Lead Sponsor

Trials

10

Recruited

300+